Cannabis Flower THC 20% (Dried Herb) (Cannatrek T20 Topaz)
Cannabis Flower THC 20% (Dried Herb) risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Cannatrek T20 Topaz, Beacon Medical Sensi Star, Kind Medical Iris.
Cannabis Flower THC 20% (Dried Herb) (brand names: Cannatrek T20 Topaz, Beacon Medical Sensi Star, Kind Medical Iris) is classified as High risk (7 risk points) by AllMeds. It is a S8 medication under the TGA in Australia. Dried flower for vaporisation, high impairment risk, driving implications
Key Takeaways
- TGA Schedule: S8 in Australia
- Risk level: High (7 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S8 | Not PBS listed |
Risk Profile
Dried flower for vaporisation, high impairment risk, driving implications
Regulatory and Compliance Guidance
When Cannabis Flower THC 20% (Dried Herb) appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S8 under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- TGA: Medicinal Cannabis Access — THC Products (S8) (2024)
THC products are Schedule 8. Require SAS-B or Authorised Prescriber pathway. Strict prescribing and monitoring requirements.
TGA regulatory framework
- Medicinal cannabis prescriptions surge in Australia (2024)
Reporting on the rapid growth of medicinal cannabis prescriptions in Australia via SAS pathway. Notes concerns about evidence base.
National broadcaster
- Cannabis-based medicines for chronic neuropathic pain — Cochrane Review (2018)
Cochrane review finding low-quality evidence that cannabis-based medicines may provide some relief for chronic neuropathic pain. Significant adverse effects noted.
Cochrane systematic review — gold standard for evidence synthesis
- SIRA: Medicinal Cannabis — S8 Requirements and Driving Impairment (2023)
SIRA notes THC products carry driving impairment risk. NSW drug-driving laws apply regardless of medical authorisation. Insurer approval required.
NSW workers comp regulator
Need to assess this medication across your caseload?
Run a full risk assessment including Cannabis Flower THC 20% (Dried Herb) interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.